GLP-1 Receptor Agonists: Transforming Weight Loss and Long-Term Health

By James O. Hill, PhD and Holly R. Wyatt, MD

For years, weight loss has felt like an uphill battle for so many. Despite their best efforts, even the most dedicated individuals have struggled to achieve and sustain meaningful weight loss. But today, we are witnessing a revolution. GLP-1 receptor agonists (GLP-1 RAs) are redefining obesity treatment, offering a breakthrough that helps millions achieve results once thought unattainable.

These medications are not just another diet trend or short-term fix. They represent a paradigm shift in how we approach obesity and metabolic health. By leveraging the body’s own biology, GLP-1 RAs drive significant weight loss, improve metabolic markers, and reduce the risk of chronic diseases. The challenge now is not just achieving weight loss but maintaining it to ensure sustainable long-term health benefits beyond the scale.

How GLP-1 Receptor Agonists Work

GLP-1 RAs have been used to treat type 2 diabetes for years but have recently become popular to support weight loss. GLP-1 RAs mimic the naturally occurring hormone GLP-1, which regulates appetite, blood sugar, and digestion. By activating this pathway, they support weight loss through multiple mechanisms:¹

Enhanced Insulin Sensitivity: These medications boost insulin secretion after meals, improving blood sugar control, particularly for those with type 2 diabetes.
Delayed Gastric Emptying: Slowing the stomach’s emptying process prolongs fullness, naturally leading to reduced calorie intake.
Increased Satiety: Users feel satisfied with smaller portions, making it easier to adhere to a healthy eating plan.
Reduced Food Noise: Many individuals report that GLP-1 medications significantly quiet the constant mental chatter about food, making weight management feel more natural and sustainable.²

GLP-1 Medications

GLP-1 (Glucagon-Like Peptide-1) is an incretin, which is a hormone released by the gut that helps regulate appetite and body weight.³
GLP-1 is primarily produced in the small intestine (L-cells) but is also secreted in smaller amounts from the colon, pancreas, and brain (hypothalamus).⁴
GLP-1 receptors (GLP-1R) are found in multiple organs, including the pancreas, brain, heart, kidneys, gastrointestinal tract, and blood vessels.⁵
GLP-1 helps regulate appetite and body weight by acting on the brain to promote satiety, reducing food intake, and slowing gastric emptying, leading to prolonged feelings of fullness.⁶

Achieving Unprecedented Weight Loss

For the first time in obesity medicine, medications consistently deliver double-digit weight loss percentages. On average, individuals taking Wegovy (semaglutide) lose around 15% of their body weight, while those on Zepbound (tirzepatide) often achieve losses greater than 20%.^7,8 These results set a new benchmark in weight loss treatment.

The benefits extend far beyond weight loss. Research shows that GLP-1 RAs lower the risk of cardiovascular disease, kidney disease, liver disease, and sleep apnea.^9,10 These medications are reshaping the perception of obesity, recognizing it as a complex medical condition with broad health implications rather than just a weight concern.

Understanding Side Effects

Like any medication, GLP-1 RAs may cause side effects. The most common include nausea, vomiting, diarrhea, constipation, and heartburn. While these can be uncomfortable, they typically improve as the body adjusts. More serious side effects, though rare, include bowel blockages, stomach paralysis, pancreatitis, kidney failure, and gallbladder disease.^9,10

Another emerging concern is the potential loss of lean muscle mass. Early research suggests that some users may lose more muscle than expected, which could impact metabolism and long-term weight maintenance. Further studies are needed, emphasizing the importance of strength training and adequate protein intake while using these medications.¹¹

The Future of Weight Loss Medications

The success of GLP-1 RAs has sparked a surge in research, with new and improved weight loss medications on the horizon. Innovations include:

Combination Therapies that pair GLP-1 drugs with other weight-loss agents for even greater effects.
Oral Formulations that eliminate the need for injections.
Personalized Treatment Plans tailored to individual metabolic responses and lifestyle needs.

This area of innovation is just getting started. The next generation of obesity treatments will offer even more effective, targeted solutions.

The Biggest Challenge: Weight Loss Maintenance

While GLP-1 RAs are game-changers for weight loss, the real question is: What happens after the weight is lost? It has long been recognized that maintaining weight loss is harder than losing it. For some, lifelong medication may be the answer, but not everyone can or wants to take these medications indefinitely.

A recent report found that of 125,474 patients initiating GLP-1 RAs, 46.5% of patients with and 64.8% without type 2 diabetes discontinued medication within 1 year. The most frequent reasons were side effects and cost.¹² Clinical trials of semaglutide found that patients who stopped the medication regained 2/3 of their weight over the following year.¹³How do we help these individuals sustain their progress?

Weight loss maintenance strategies could include:

Long-Term Medication Use: For some, staying on GLP-1 RAs indefinitely may be the best option. These drugs are designed for chronic use, and data suggests they remain safe and effective over time. However, adding lifestyle changes may improve health and quality of life beyond the scale.
Optimizing Lifestyle Interventions: We need new lifestyle programs specifically designed for people who have lost weight on medication. Historically, weight loss and weight maintenance programs have been lumped together, but they require different strategies.
Combination Approaches: Some individuals may benefit from a blended approach, using medication intermittently or at a lower dose while incorporating structured lifestyle interventions. Others might transition to non-GLP-1 medications like phentermine to help sustain their progress.

Much remains to be developed, but it is clear that weight maintenance must be an intentional, structured process. This is where dietitians, clinicians, and health professionals play a critical role. Innovative, evidence-based approaches to support people in keeping the weight off are needed.

The New Era of Obesity Treatment

GLP-1 RAs are not a silver bullet, but they are a powerful tool in the treatment of obesity. They have redefined what is possible, offering hope to millions who have struggled for years. But this is just the beginning. The real challenge is ensuring that weight loss is not only achieved but maintained. As we move forward, we must rethink our approach to obesity treatment. How do we create better weight maintenance strategies? How do we personalize treatments to fit individual needs? And how do we help people not just lose weight but transform their health for life?

Sustaining weight loss requires a shift in focus from short-term success to long-term health and quality of life. Healthcare providers must take the lead in developing better strategies, supporting patients beyond initial weight loss, and ensuring that treatment evolves with the science. The path forward is clear, and what we do next will define the future of obesity care.

REFERENCES

Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. The Lancet Gastroenterology & Hepatology. 2024 Oct 1;9(10):957-64.
Diktas HE, Cardel MI, Foster GD, LeBlanc MM, Dickinson SL, Ables EM, Chen X, Nathan R, Shapiro D, Martin CK. Development and validation of the Food Noise Questionnaire. Obesity. 2025 Jan 19.
Drucker, D. J. (2020). Mechanisms of action of GLP-1 in diabetes and obesity. The Lancet Diabetes & Endocrinology, 8(5), 377-388.
Pratley, R. E., & Nauck, M. A. (2021). The clinical pharmacology of GLP-1 receptor agonists: Implications for the management of type 2 diabetes. Diabetes Care, 44(10), 2363-2372.
Lindgren, O., & Nystrom, T. (2020). GLP-1 receptor signaling in metabolic and cardiovascular diseases. Trends in Endocrinology & Metabolism, 31(5), 335-346.
Zhao, C., Zong, G., & Jiang, Y. (2022). The role of GLP-1 in regulating glucose and lipid metabolism. Current Diabetes Reviews, 18(2), 135-142.
Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216.
Drucker DJ. The benefits of GLP-1 drugs beyond obesity. Science. 2024 Jul 19;385(6706):258-60.
Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024 Jun 6:dci240003.
Tinsley GM, Heymsfield SB. Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. Journal of the Endocrine Society. 2024 Nov;8(11):bvae164.
Rodriguez PJ, Zhang V, Gratzl S, Do D, Cartwright BG, Baker C, Gluckman TJ, Stucky N, Emanuel EJ. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. 2025 Jan 2;8(1):e2457349-.
Wilding JP, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022 Aug;24(8):1553-64.